UAE approves Lipfendra for high cholesterol as second global market

The UAE Ministry of Health and Prevention (MoHAP) has granted regulatory approval for Lipfendra, a medication designed to treat high cholesterol, making the Emirates the second nation globally to authorize the drug. The decision follows a rigorous review of clinical trial data regarding the medication’s efficacy in lowering low-density lipoprotein (LDL) levels in patients with primary hypercholesterolemia and mixed dyslipidemia. Clinical Efficacy and Patient Access Lipfendra functions by inhibiting specific enzymes in the liver that contribute to the production of cholesterol. Clinical data submitted to UAE regulators indicates that the treatment can reduce LDL cholesterol by up to 15% to 20% when used in conjunction with maximum tolerated statin therapy. Healthcare providers in the UAE are expected to begin prescribing the medication to eligible patients within the coming weeks as supply chains stabilize. This approval follows the drug's initial authorization in the United States, positioning the UAE as an early adopter of the pharmaceutical intervention. The Ministry stated that the approval is part of a broader effort to reduce the prevalence of cardiovascular diseases, which remain a leading cause of mortality in the region. Impact on UAE Healthcare The introduction of Lipfendra is expected to affect thousands of UAE residents who struggle with statin intolerance or those whose cholesterol levels remain uncontrolled despite existing treatments. Cardiology departments…